Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy‐based treatment for NSCLC 🔗 Access full article via ACS CancerCancer, Volume 130, Issue 4, Page 495-496, 15 February 2024. Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
